This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.

Detailed Description
-----------------
In 2008, a change in the agalsidase alfa drug substance manufacturing process was made. There are no changes to the drug product formulation, manufacturing site, manufacturing process, or container closure. An agalsidase alfa bioreactor manufacturing process (agalAF1) utilizing animal component-free media replaced the previous roller bottle (RB) process. This study is designed to provide PD/PK and safety data. The assessment schedule is designed to capture the PK profile of drug uptake in the blood as well the pharmacologic effect which manifests over the course of weeks. Each patient will serve as his own control.

Official Title
-----------------
A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease

Conditions
-----------------
Fabry Disease

Intervention / Treatment
-----------------
* Biological: agalsidase alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must be diagnosed with Fabry disease using the following criteria: The patient is a hemizygous male with Fabry disease as confirmed by a deficiency of α-galactosidase A activity measured in serum, leukocytes, or fibroblasts or has a confirmed mutation of the α-galactosidase A gene. Patient is male and between 18 and 65 years of age, inclusive. Patient must be willing to remain in the clinic as required by the study and comply with the procedures and evaluations of the study. At the time of confirmation of study eligibility visit, patients must have received at least 26 weeks of treatment with RB Replagal at a dose of 0.2 mg/kg administered IV EOW. Patient provides informed consent. Patients who are naive to ERT: 1. Treatment naive patients must have a pretreatment plasma Gb3 level above the normal range (if value is available). Exclusion Criteria: Patient is unable to be venipunctured and/or tolerate venous access. Patient has tested positive for anti-agalsidase alfa antibodies either at screening or confirmation of eligibility visit. Patient had pre-ERT plasma Gb3 levels within the normal range (if value is available). Patient is participating in any other Shire HGT investigational study. Patient is currently on dialysis, is expected to begin dialysis during the study, has received a kidney transplant, or is on the renal transplant waiting list. Patient is unable to comply with the protocol (eg, clinical relevant medical condition making implementation of the protocol difficult, unstable social situation, or otherwise unlikely to complete the study) or is, in the opinion of the Investigator, otherwise unsuited for the study. The patient is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device), except for the Canadian Fabry Disease Initiative, within 6 months prior to receiving the first dose of AF Replagal in this study or at any time during the study. The patient has previously received AF Replagal prior to study entry.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Replagal® (0.2 mg/kg, IV, EOW)<br>Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0) Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF | Biological: agalsidase alfa<br> <br> * Other names: Replagal;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels |  | Baseline to EOS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline to Week 16 (EOS) in Plasma Gb3 Levels |  | Baseline to EOS | 
| Dose-normalized Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast/Dose) | The dose-normalized calculation was performed by dividing the pharmacokinetic parameter by the administered dose. | Week 0 to Week 14 | 
| Dose-normalized AUC Extrapolated to Infinity (AUC∞/Dose) | The dose-normalized calculation was performed by dividing the pharmacokinetic parameter by the administered dose. | Week 0 to Week 14 | 
| Dose-normalized Maximum Serum Concentration (Cmax/Dose) | The dose-normalized calculation was performed by dividing the pharmacokinetic parameter by the administered dose. | Week 0 to Week 14 | 
| To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status (in Serum) at End of Study |  | EOS | 
| Overall Summary of TEAEs by Treatment (Replagal RB and Replagal AF) | To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status, concomitant medication, vital signs and ECG. | Week 2 to EOS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Replagal